CASSAVA SCIENCES
Cassava Sciences is a clinical-stage biopharmaceutical company focused on neuroscience. We translate novel scientific insights into new medicines. That’s a drastic challenge. Our work is complex, risky, labor-intensive, persistent and expensive.
CASSAVA SCIENCES
Social Links:
Industry:
Biopharma Biotechnology Life Science Medical Neuroscience Pharmaceutical
Founded:
1998-01-01
Address:
Austin, Texas, United States
Country:
United States
Website Url:
http://www.cassavasciences.com
Total Employee:
1+
Status:
Active
Contact:
(512) 501 - 2444
Total Funding:
206.9 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail ReCAPTCHA GoDaddy DNS ReCAPTCHA V2 Akamai Hosted Time Warner
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
National Institutes of Health
National Institutes of Health investment in Grant - Cassava Sciences
National Institutes of Health
National Institutes of Health investment in Grant - Cassava Sciences
National Institutes of Health
National Institutes of Health investment in Grant - Cassava Sciences
Official Site Inspections
http://www.cassavasciences.com Semrush global rank: 1.51 M Semrush visits lastest month: 17.75 K
Unable to get host informations!!!
More informations about "Cassava Sciences"
Investor Relations - Cassava Sciences, Inc.
Jul 22, 2024 Webcast planned for Monday, November 25th at 8:00 AM ET AUSTIN, Texas , Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on …See details»
Cassava Sciences - Wikipedia
Cassava Sciences was founded by Remi Barbier in May 1998 as Pain Therapeutics, focusing on opioids and chronic pain. Barbier first heard of the research led by Stanley M. Crain at the Albert Einstein College of Medicine in New York City around 1993. Crain invited Barbier to his lab and explained the potential pharmaceutical and financial benefits. In 1998, Barbier started Pain Therapeutics, Inc. in South San Francisco, California, with an initial investment of $1 million. See details»
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
Nov 18, 2024 Freda Nassif, Chief Commercial Officer of Cassava commented, “I am honored to have the opportunity to lead the commercial organization for a novel therapy at a time in which …See details»
Cassava Sciences, Inc. (SAVA) Company Profile & Facts - Yahoo …
See the company profile for Cassava Sciences, Inc. (SAVA) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Cassava Sciences to Hold Corporate Update on November 25th
5 days ago Company Eric Schoen, Chief Financial Officer(512) [email protected] [email protected]. Source: Cassava Sciences, …See details»
Cassava Sciences - Crunchbase Company Profile & Funding
Cassava Sciences reported its full-year 2023 financial results and corporate updates. The company experienced a significant stock price drop of 46% following the indictment of an adviser.See details»
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
Nov 18, 2024 Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava’s commercial …See details»
Cassava Sciences, Inc. Company Profile | Austin, TX | Competitors ...
Find company research, competitor information, contact details & financial data for Cassava Sciences, Inc. of Austin, TX. Get the latest business insights from Dun & Bradstreet.See details»
Cassava Sciences to Hold Corporate Update on November 25th
5 days ago [email protected]. Company Eric Schoen, Chief Financial Officer (512) 501-2450 [email protected] ...See details»
PRESS RELEASES - Cassava Sciences, Inc.
Sep 24, 2024 Webcast planned for Monday, November 25th at 8:00 AM ET AUSTIN, Texas , Nov. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical …See details»
Cassava Sciences Selects Clinical Research Organization for
Jun 21, 2021 Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease ... [email protected] (512) 501-2450.See details»
Cassava Sciences, Inc. (SAVA) - Yahoo Finance Canada
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small …See details»
Cassava Sciences Provides Mid-Year Corporate Update, Clinical ...
Jun 21, 2021 A clinical research organization (CRO) has been selected and will be publicly announced shortly. Large-scale, cGMP drug production capabilities are in-place to support the …See details»
Cassava Sciences Announces Significant Program Progress and …
For more information, please visit: https://www.CassavaSciences.com For More Information Contact:Eric Schoen, Chief Financial [email protected](512) 501-2450 …See details»
Cassava Sciences Announces Completion of an Interim Safety …
Mar 25, 2024 The second Phase 3 trial (NCT05026177) has a 76-week treatment period; 1,125 Alzheimer’s patients were randomized into this trial, as announced in November 2023.See details»
Cassava Sciences Names Rick Barry as Chief Executive Officer
Sep 9, 2024 Claude Nicaise, M.D. appointed Chairman of the Board. AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology …See details»
Cassava Sciences Provides Mid-Year Corporate Update,
Jun 21, 2021 A clinical research organization (CRO) has been selected and will be publicly announced shortly. Large-scale, cGMP drug production capabilities are in-place to support the …See details»
Cassava Sciences Announces Positive Data with SavaDx from a …
AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced positive clinical data with SavaDx, an investigational diagnostic/biomarker to …See details»
Cassava Sciences Announces Significant Program Progress and …
AUSTIN, Texas, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s …See details»